Over the past few years, semaglutide medications such as Ozempic, Wegovy, and Rybelsus have transformed the treatment of type 2 diabetes and obesity. Their rapid adoption has reshaped treatment, sparked widespread public interest, and introduced new considerations for healthcare providers—including dentists. In this CDA Oasis discussion, Dr. Aviv Ouanounou, a dental pharmacologist and Associate Professor […]
CDA Oasis is delighted to present the 2025-26 CDA Honours and Awards Program recipients. Each year the CDA Awards recognize individuals across the country who have demonstrated unwavering passion and support for the dental profession in Canada and exhibited consistent commitment to the oral health of Canadians. This year’s awards were presented at a dedicated […]